Structure Therapeutics Inc. American Depositary Shares (NASDAQ:GPCR) — Market Cap & Net Worth
Market Cap & Net Worth: Structure Therapeutics Inc. American Depositary Shares (GPCR)
Structure Therapeutics Inc. American Depositary Shares (NASDAQ:GPCR) has a market capitalization of $2.99 Billion ($2.99 Billion) as of May 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4944 globally and #1579 in its home market, demonstrating a -10.23% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Structure Therapeutics Inc. American Depositary Shares's stock price $42.21 by its total outstanding shares 70841812 (70.84 Million). Analyse Structure Therapeutics Inc. American Dep cash conversion from operations to see how efficiently the company converts income to cash.
Structure Therapeutics Inc. American Depositary Shares Market Cap History: 2023 to 2026
Structure Therapeutics Inc. American Depositary Shares's market capitalization history from 2023 to 2026. Data shows growth from $2.89 Billion to $2.99 Billion (37.57% CAGR).
Index Memberships
Structure Therapeutics Inc. American Depositary Shares is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.41 Trillion | 0.12% | #116 of 976 |
|
NASDAQ Composite
IXIC
|
$38.77 Trillion | 0.01% | #540 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.67 Trillion | 0.18% | #73 of 263 |
Weight: Structure Therapeutics Inc. American Depositary Shares's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Structure Therapeutics Inc. American Depositary Shares Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Structure Therapeutics Inc. American Depositary Shares's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GPCR by Market Capitalization
Companies near Structure Therapeutics Inc. American Depositary Shares in the global market cap rankings as of May 4, 2026.
Key companies related to Structure Therapeutics Inc. American Depositary Shares by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Structure Therapeutics Inc. American Depositary Shares Historical Marketcap From 2023 to 2026
Between 2023 and today, Structure Therapeutics Inc. American Depositary Shares's market cap moved from $2.89 Billion to $ 2.99 Billion, with a yearly change of 37.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.99 Billion | -39.31% |
| 2025 | $4.93 Billion | +160.15% |
| 2024 | $1.89 Billion | -34.41% |
| 2023 | $2.89 Billion | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Structure Therapeutics Inc. American Depositary Shares was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.99 Billion USD |
| MoneyControl | $2.99 Billion USD |
| MarketWatch | $2.99 Billion USD |
| marketcap.company | $2.99 Billion USD |
| Reuters | $2.99 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Structure Therapeutics Inc. American Depositary Shares
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment… Read more